Resources

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 2 of this Exclusive Interview, Dr. Taub explains the use and effects of the latest cholesterol drugs, PCSK9-inhibitors. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who focuses on general …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 3 of this Exclusive Interview, Dr. Taub discusses the possible negative effects of PCSK9 Inhibitors. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who focuses on general and preventive cardiology. …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 4 of this Exclusive Interview, Dr. Taub explains when and how she continues to work with diabetes patients versus referring them to a specialist. Dr. Pam R. Taub, MD, FACC is a …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 5 of this Exclusive Interview, Dr. Taub explains her effective methods of treating the patient that may benefit other medical professionals. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 6 of this Exclusive Interview, Dr. Taub discusses calcium scores and starting patients on PCSK9. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who focuses on general and preventive cardiology. …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 7 of this Exclusive Interview, Dr. Taub explains her comfort level with the newest drugs. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who focuses on general and preventive cardiology. …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 8, the conclusion of this Exclusive Interview, Dr. Taub shares her findings after using new medications with her patients. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who focuses on …

Man, 51 years of age, type 1 diabetes for 32 years. Patient also has history of Class II obesity, CVA, MI and insulin resistance. Patient referred to Obesity Center for weight loss. A1c was 8.2%. Plan was to start Symlin. Symlin was added at 30mcg daily before dinner. I recommended he get a CGM. He did.

Dr. Altamash Shaikh talks with Diabetes in Control Associate Medical Editor Joy Pape at the 2016 AACE Meeting. In part 1 of this Exclusive Interview, Dr. Shaikh explains the current state of diabetes in India and the needs required to help this population to manage this condition.

In this week's Homerun Slides, the vital stats of patients on the placebo and empagliflozin 10- and 25-gram study.